2022
Inhaled Bacteriophage Therapy for Multi-Drug Resistant Achromobacter.
Winzig F, Gandhi S, Lee A, Würstle S, Stanley G, Capuano I, Neuringer I, Koff J, Turner P, Chan B. Inhaled Bacteriophage Therapy for Multi-Drug Resistant Achromobacter. The Yale Journal Of Biology And Medicine 2022, 95: 413-427. PMID: 36568830, PMCID: PMC9765334.Peer-Reviewed Original ResearchConceptsCF patientsCystic fibrosisChronic pulmonary infectionGlobal public health threatBacterial lung infectionsChallenging clinical problemPublic health threatChronic bacterial lung infectionsPulmonary infectionRespiratory statusLung infectionClinical problemBacteriophage therapyInfectionAntimicrobial-resistant bacteriaTherapyHealth threatPhage therapyPatientsAMR infectionsResistant bacteriaLytic bacteriophagesPossible benefitsChemical antibioticsCurrent study
2018
Epidemiology of antimicrobial resistance in Lebanese extra-hospital settings: An overview
Osman M, Al Mir H, Rafei R, Dabboussi F, Madec J, Haenni M, Hamze M. Epidemiology of antimicrobial resistance in Lebanese extra-hospital settings: An overview. Journal Of Global Antimicrobial Resistance 2018, 17: 123-129. PMID: 30553113, DOI: 10.1016/j.jgar.2018.11.019.Peer-Reviewed Original ResearchConceptsAntimicrobial resistanceExtra-hospital settingsTerms of mortalityMiracle drugAntimicrobial-resistant pathogensNon-clinical settingsSignificant morbidityClinical settingNovel drugsAntimicrobial-resistant bacteriaMultidrug-resistant bacterial strainsSocietal costsInappropriate useCombat infectionEpidemiological situationMorbidityMortalityEpidemiologyDrugsAntibioticsVeterinary medicineAMR crisisMajority of investigations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply